User:Aodidi
 | This user page or section is in a state of significant expansion or restructuring. You are welcome to assist in its construction by editing it as well. If this user page has not been edited in several days, please remove this template. If you are the editor who added this template and you are actively editing, please be sure to replace this template with {{in use}} during the active editing session. Click on the link for template parameters to use.
This page was last edited by Ottawahitech (talk | contribs) 12 years ago. (Update timer) |
| Company type | Public (TSX: I) (Nasdaq: IPCI) |
|---|---|
| Industry | Biotechnology Pharmaceutical |
| Founded | 1998 |
| Founder | Dr. Isa Odidi Dr. Amina Odidi |
| Headquarters | Toronto, Ontario, Canada |
Area served | North America |
| Products | Medicine Drugs Controlled Release Drugs |
| Website | www.intellipharmaceutics.com |
IntelliPharmaCeutics (TSX: I) is a Canadian specialty pharmaceutical company, operating internationally and primarily engaged in the research, development, and commercialization of controlled-release and targeted pharmaceutical products.
Disclosed Product Pipeline
[edit]Focalin XR
[edit]Dexmethylphenidate XR is a generic version of the marketed drug Focalin XR®, which is partnered with Par Pharmaceutical (5, 10, 15, 20 mg strengths) and is currently the subject of an Abbreviated New Drug Application (ANDA) filing with the U.S. Food and Drug Administration (FDA).
Focalin XR® is an extended-release formulation of dexmethylphenidate and is indicated for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in patients aged 6 years and older. ADHD is one of the most common childhood disorders and can continue through adolescence and adulthood.
In December 2010, IntelliPharmaCeutics filed an ANDA with the FDA for approval to market a generic of the 30 mg strength of Focalin XR.[1]
Venladaxine XR/Effexor XR
[edit]Venlafaxine XR is a generic version of the marketed drug Effexor XR®. This product is currently the subject of an Abbreviated New Drug Application(ANDA) filing with the U.S. Food and Drug Administration (FDA).[2]
Effexor XR® is an extended-release capsule for oral administration that contains venlafaxine hydrochloride. It is indicated for the treatment of symptoms of major depressive disorder, generalized anxiety disorder, social anxiety disorder, and panic disorder.
Pantoprozole XR/Protonix XR
[edit]IntelliPharmaCeutics' Pantoprozole XR is a delayed release pantoprazole sodium, a generic version of the marketed drug Protonix®. This product is currently the subject of an Abbreviated New Drug Application (ANDA) filing with the U.S. Food and Drug Administration (FDA).
Protonix® is a delayed-release capsule for oral administration that contains pantoprazole sodium. Protonix inhibits gastric acid secretion and is prescribed for the short-term treatment of conditions such as stomach ulcers associated with gastroesophageal reflux disease as well as the long term treatment of pathological hypersecretory conditions including Zollinger-Ellison syndrome.[3]
Rexista
[edit]Rexista is one of IntelliPharmaCeutics non-generic development products. It is an abuse- and alcohol-resistant, controlled-release oral oxycodone formulation. This product is covered by pending patent applications. Rexista™ is a unique dosage form, designed to be resistant to well-documented abuse that is experienced with current oxycodone products. This includes abuse by injection when combined with solvents and by nasal inhalation when crushed or powdered.[4] Rexista™ is also designed to resist release of the entire dose when consumed with alcohol, a significant problem with some opioid drugs, such as hydromorphone.[5]
The pilot clinical trial produced the following results[6]:
- The Rexista™ product demonstrated sustained release pharmacokinetic activity, with blood plasma concentrations at clinically significant levels over a 24 hour period.
- The bioavailability of a single dose of the Rexista™ product, as measured by Cmax and AUC, was comparable to that of two doses of Oxycontin® dosed at 12 hour intervals. Both Cmax and AUC were in the 80% - 125% range as compared to Oxycontin®, demonstrating effective bioequivalence with the branded product.
